Boston Scientific Corp. (BSX)

mislania (26.75) Submitted: 3/15/07 5:17 PM : Start Price: $14.91 BSX Score: -5.12

What else can go wrong? I think people forget that BSX is a leader in its field. The market has bid down bsx to a valuation that provides a large margin of safety. In the coming months the market will start focusing on the business and the price will...

Report this Post Replies: 0 | Reply | Permalink

NetscribeMedDevs (95.52) Submitted: 2/23/07 12:16 AM : Start Price: $17.15 BSX Score: 12.35

Beginning its life by acquiring equity interest in a research and development firm relating to surgical alternatives, the company started by John Abele and Pete Nicholas has come a long way with revenues growing to the tune of $6.3 billion during a s...

Report this Post Replies: 1 | Reply | Permalink

Chiefsarebest (93.46) Submitted: 10/25/06 9:48 AM : Start Price: $14.55 BSX Score: -7.41

Way over paid for Guidant the stock price has I believe fully adjusted for this monumental error. Stock has bottomed and growth prospects are good. Litigation & recall risk is also in the stock price. This stock is NOT the best in its class, but i...

Report this Post Replies: 0 | Reply | Permalink

tracyrees (98.95) Submitted: 10/09/06 6:43 PM : Start Price: $14.55 BSX Score: -5.98

Demographics are on their side. Aging boomers will drive revenue for many years to come. Guidant acquisition gives them great supplier pricing power. Revenue and margins will improve.

Report this Post Replies: 0 | Reply | Permalink

ottodigbi (< 20) Submitted: 8/23/06 10:24 AM : Start Price: $16.87 BSX Score: -21.52

Bsx had a torrid time recently after it had a major recall of heart defibulator equipment supplied by Guident a company which it recently tookover.When Guident is properly bedded in bsx is set to outperform .Fundamentally sound -with plenty of cash i...

Report this Post Replies: 1 | Reply | Permalink

5761 (< 20) Submitted: 10/22/07 9:13 AM : Start Price: $14.29 BSX Score: 4.47

finally cleaning up expenses and head count which should have been done 12 months ago. Management was a little slow in getting started but they seem to "get it" now. Debt will come down and non strategic businesses will be sold. Coated stents will ...

Report this Post Replies: 0 | Reply | Permalink

davescharf (33.81) Submitted: 10/06/06 12:19 AM : Start Price: $14.77 BSX Score: 7.31

Too much debt due to Guidant acquisition and slowing CRM market will make this sotck languish for at least next 2 years.

Report this Post Replies: 0 | Reply | Permalink

minneapolistrade (56.29) Submitted: 3/13/08 10:27 PM : Start Price: $12.93 BSX Score: 3.58

Coming out of the Guidant merger and shedding some weight, Boston Scientific is poised to lead the pack in the medical device arena. The health care industry tends to be a little more recession proof than most and med device is an ever changing area ...

Report this Post Replies: 1 | Reply | Permalink

guitarpsych (49.60) Submitted: 9/27/06 11:34 PM : Start Price: $14.79 BSX Score: -8.15

Value play, out of favor stock and industry. But demographics are on cardiology device manufacturer's side and drug eluting stents are still in their infancy. Rock bottom pricing

Report this Post Replies: 0 | Reply | Permalink

shravankrish (42.82) Submitted: 12/01/07 4:20 PM : Start Price: $12.21 BSX Score: 16.92

Despite the fact that Xience will probably steal marketshare from Boston Scientific over the next couple of years, Guidant gives BSX much needed diversification and once the dust settles from the acquisition, the company's finances will improve.

Report this Post Replies: 0 | Reply | Permalink